HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor
ERBB2/HER2 is a therapeutic target in DSRCT. HER2 ADCs may represent novel options for managing this exceptionally aggressive sarcoma, possibly fulfilling an urgent and historically unmet need for more effective clinical therapy.
Authors
- Raymond G. Dematteo
- Elisa de Stanchina (ORCID: https://orcid.org/0000-0002-3873-315X)
- Inna Khodos
- Zebing Liu (ORCID: https://orcid.org/0000-0003-4682-1253)
- Jenna-Marie Dix (ORCID: https://orcid.org/0000-0001-8822-4049)
- Tom Zhang (ORCID: https://orcid.org/0009-0007-0979-9719)
- Igor Odintsov (ORCID: https://orcid.org/0000-0001-8073-8803)
- Romel Somwar
- Marc Ladanyi (ORCID: https://orcid.org/0000-0001-9055-7213)
- Murray J. Tipping (ORCID: https://orcid.org/0000-0001-5262-2723)
- Marissa S. Mattar (ORCID: https://orcid.org/0000-0002-2846-9914)
- Irina Linkov (ORCID: https://orcid.org/0000-0001-7520-5359)
- Ryan Cheng (ORCID: https://orcid.org/0000-0002-7154-5353)
- Allan J.W. Lui (ORCID: https://orcid.org/0000-0001-7624-3437)
- Charlene Kwong
- Jeanine Lisanti
- Leo Gili
- Christopher A. Febres‐Aldana
Institutions
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- New York Medical College (US)
- Shanghai Jiao Tong University (CN)
- University of Cambridge (GB)
- Renji Hospital (CN)
- Cancer Research UK (GB)
- Stony Brook School (US)
- Stony Brook University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1835
- Citations
- 13
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- Bristol-Myers Squibb
- AstraZeneca
- National Institutes of Health
- Loxo Oncology
- National Cancer Institute